M
Martin Olivo
Researcher at Eisai
Publications - 33
Citations - 1415
Martin Olivo is an academic researcher from Eisai. The author has contributed to research in topics: Eribulin & Metastatic breast cancer. The author has an hindex of 10, co-authored 28 publications receiving 826 citations. Previous affiliations of Martin Olivo include Hebron University & BC Cancer Agency.
Papers
More filters
Journal ArticleDOI
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia,Sara A. Hurvitz,Sara M Tolaney,Delphine Loirat,Kevin Punie,Mafalda Oliveira,Adam M Brufsky,Sagar D Sardesai,Kevin Kalinsky,Amelia Zelnak,Robert Weaver,Tiffany A. Traina,Florence Dalenc,Philippe Aftimos,Filipa Lynce,Sami Diab,Javier Cortes,Joyce O'Shaughnessy,Véronique Diéras,Cristiano Ferrario,Peter Schmid,Lisa A. Carey,Luca Gianni,Martine Piccart,Sibylle Loibl,David M. Goldenberg,Quan Hong,Martin Olivo,Loretta M. Itri,Hope S. Rugo +29 more
TL;DR: The Sacituzumab govitecan (SgoVitecan) is an antibody-drug conjugate composed of an antibody targeting the human tro... as mentioned in this paper.
Journal ArticleDOI
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Peter P.A. Kaufman,Ahmad Awada,Chris Twelves,Louise Yelle,Edith A. Perez,Galina Velikova,Martin Olivo,Yi He,Corina E. Dutcus,Javier Cortes +9 more
TL;DR: In this article, the authors compared eribulin with capecitabine in patients with locally advanced or metastatic breast cancer (MBC) who had received prior anthracycline-and taxane-based therapy.
Journal ArticleDOI
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan Ellard,Mark Clemons,Karen A. Gelmon,B. Norris,Hagen F. Kennecke,Stephen Chia,Kathleen I. Pritchard,Andrea Eisen,T. Vandenberg,Marianne Taylor,Eric Sauerbrei,Moshe Mishaeli,David G. Huntsman,Wendy Walsh,Martin Olivo,L. McIntosh,Lesley Seymour +16 more
TL;DR: Oral everolimus has activity in metastatic breast cancer that is schedule dependent and no biologic correlates of response could be identified, although there were trends favoring benefit in ER-positive and HER2-negative metastatic Breast cancer.
Journal ArticleDOI
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Aditya Bardia,Sara M. Tolaney,Kevin Punie,Delphine Loirat,Mafalda Oliveira,Kevin Kalinsky,Kevin Kalinsky,Amelia Zelnak,Philippe Aftimos,Florence Dalenc,Sagar Sardesai,Erika Hamilton,Priyanka Sharma,S. Recalde,E.C. Gil,Tiffany A. Traina,Joyce O'Shaughnessy,Javier Cortes,Michaela Tsai,L. Vahdat,Véronique Diéras,Lisa A. Carey,Hope S. Rugo,David M. Goldenberg,Q. Hong,Martin Olivo,L.M. Itri,Sara A. Hurvitz +27 more
TL;DR: In this article, the authors evaluated the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes and showed that SG benefits patients with previously treated triple-negative breast cancer expressing high/medium Trop 2 compared with standard-of-care chemotherapy and regardless of germline bRCA 1/2 status.
Proceedings ArticleDOI
Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Sara M. Tolaney,Kevin Kalinsky,Virginia G. Kaklamani,Claudio Savulsky,Martin Olivo,Gursel Aktan,Peter A. Kaufman,D Xing,A Almonte,S Misir,Vassiliki Karantza,Sami Diab +11 more
TL;DR: ERI+PEM was well tolerated and demonstrated activity in pts with mTNBC, and the combination resulted in improved ORR, with longer PFS, OS, and comparable TEAEs to those observed with either treatment as monotherapy.